Seattle, WA (PRWEB) October 28, 2013
ReachBio LLC (Seattle, WA, USA) announced today that it has signed an agreement with PeloBiotech GmbH (Munich, Germany) giving PeloBiotech exclusive distribution rights to ReachBio’s full product line for the life science research market within Germany, Austria and Switzerland.
ReachBio provides research products and contract services for applications in basic life science research, drug research & development and toxicology. The company’s main product lines consist of ColonyGel™ methylcellulose-based media for hematopoietic colony-forming cell (CFC) assays and cryopreserved normal human primary cells isolated from blood, cord blood and bone marrow.
The extensive ColonyGel™ semi-solid media product line includes multiple formulations with different cytokine (growth factor) combinations optimized for the growth of the different progenitor cells in blood and bone marrow. In the cytokine-optimized, semi-solid environment provided by ColonyGel™, the different progenitors grow as morphologically distinct three-dimensional colonies that can be identified and scored microscopically. The ColonyGel™ line-up also includes formulations optimized for different species, including human, mouse, rat, dog and non-human primate. Applications of CFC assays using ColonyGel™ media include research into normal and abnormal hematological development, leukemia and cancer stem cells, cell therapy, stem cell biology, investigative toxicology, etc.
ReachBio’s line of normal primary human cells include highly purified cell types from blood such as the various subsets of T lymphocytes, B lymphocytes, natural killer cells and monocytes. It also includes “ReachBio Qualified” CD34+ and CD133+ stem cells/primitive progenitors purified from cord blood and bone marrow that have been pre-qualified in CFC assays. ReachBio also specializes in providing customized cell isolation services for custome
Copyright©2012 Vocus, Inc.
All rights reserved